Department of Pediatrics
Administration, Inhalation; Anti-Bacterial Agents; use; Aztreonam; Cystic Fibrosis; Drug Discovery; Humans; Lysine; Pseudomonas Infections; Pseudomonas aeruginosa; Treatment Outcome
Allergy and Immunology | Pediatrics | Respiratory Tract Diseases
In February 2010, aztreonam for inhalation solution (Cayston; Gilead) - an inhalable formulation of the monobactam antibiotic aztreonam and lysine - was approved by the US FDA to improve respiratory symptoms in patients with cystic fibrosis infected with Pseudomonas aeruginosa.
DOI of Published Version
Nat Rev Drug Discov. 2010 May;9(5):357-8. Link to article on publisher's site
Nature reviews. Drug discovery
O'Sullivan BP, Yasothan U, Kirkpatrick P. (2010). Inhaled aztreonam. Pulmonary and Allergy. https://doi.org/10.1038/nrd3170. Retrieved from https://escholarship.umassmed.edu/peds_pulmonary/46